EPHEDRINE MARKET ANALYSIS

Regional Analysis

Global Ephedrine Market – Regional Insights

North America accounted for the largest market share in 2018, owing to launches and approvals of new ephedrine products in the region. For instance, in March 2017, Akorn, Inc., a developer and manufacturer of generics and branded prescription pharmaceuticals, received the U.S. Food and Drug Administration (FDA) approval for its New Drug Application (NDA) for single dose ampule of an ephedrine sulfate injection which is indicated for treating hypotension occurring during spinal anesthesia.

Increasing ephedrine product launches is expected to propel the market growth in the Europe region. For instance, in April 2016, Avadel Pharmaceuticals, formerly known as Flamel Technologies, received approval from the U.S. Food and Drug Administration for Akovaz, an ephedrine sulfate injection, which will be used to treat hypotension occurring during anesthesia. 

Moreover, high prevalence of hypotension during spinal anesthesia in Asia Pacific is likely to drive the ephedrine market over the forecast period. For instance, according to a study published in the Indian Journal of Anesthesia, 2018, the cases of mild, moderate, and severe spinal anesthesia induced hypotension was approximately 20%, 35%, and 40% respectively.